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Background. Osteopontin (OPN) is reported to have two dis-
tinct functions in kidney disease: Promotion of inflammation at
sites of tissue injury, and inhibition of calcium oxalate monohy-
drate stone formation. However, many of the studies supporting
these functions were carried out in animal models of acute renal
injury or in cultured cells; thus, the role of OPN in chronic renal
disease is not well defined. We examined the role of OPN in ade-
nine phosphoribosyltransferase (Aprt) knockout mice, in which
inflammation and formation of 2,8-dihydroxyadenine (DHA)
kidney stones are prominent features, by generating Aprt/Opn
double knockout mice.
Methods. We characterized the phenotypes of six- and
12-week-old Aprt−/− Opn−/−, Aprt−/− Opn+/+, Aprt+/+
Opn−/−, and Aprt+/+ Opn+/+ male and female mice using
biochemical, histologic, immunohistochemical, and in situ hy-
bridization techniques.
Results. At 6 weeks of age, there was no difference in phe-
notype between double knockout and Aprt knockout mice. At
12 weeks, there was increased adenine and DHA excretion, re-
nal crystal deposition, and inflammation in double knockout
versus Aprt knockout male mice. Double knockout and Aprt
knockout female mice at 12 weeks had less pathology than
their male counterparts, but kidneys from double knockout fe-
males showed more inflammation compared with Aprt knock-
out females; both genotypes had similar levels of DHA crystal
deposition.
Conclusion. We conclude that (1) OPN is a major inhibitor of
DHA crystal deposition and inflammation in male mice; and (2)
OPN is a major modifier of the inflammatory response but not
of crystal deposition in female mice. Thus, separate mechanisms
appear responsible for the tissue changes seen in DKO males
versus females.
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inflammation, kidney stone disease, osteopontin, xanthine dehydroge-
nase.
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Many natural inhibitors of kidney stone formation
have been identified in urine, but inhibitors affecting cal-
cium oxalate monohydrate stone formation have been
the most widely studied [1]. Urinary proteins with in-
hibitory activity include bikunin, osteopontin (OPN),
prothrombin fragments, and Tamm-Horsfall protein [2–
8]. Most of these proteins are anionic, with many acidic
amino acid residues, and they frequently contain post-
translational modifications such as phosphorylation or
glycosylation. The inhibitors appear to bind to calcium
oxalate surfaces [9], but the structural features that favor
crystal binding and subsequent inhibition of stone for-
mation are not fully understood. The inhibitory effects
of OPN on stone formation are likely to be dependent
on the phosphorylation state of OPN, with higher levels
causing more inhibition of crystal nucleation and aggre-
gation [10]. In normal mouse kidney, OPN expression
was observed primarily in the thick ascending limbs of
the loop of Henle and in distal convoluted tubules [11].
In human kidney, OPN expression has been observed in
the descending loop of Henle, collecting ducts, and the re-
nal papilla [12], sites that are considered to be associated
with the onset of stone formation. An increase in OPN ex-
pression has been demonstrated in proximal tubular ep-
ithelium in humans following cyclosporine toxicity and in
rodent models of renal injury [13], including kidneys from
calcium oxalate monohydrate stone forming rats [14, 15].
OPN also is reported to be a promoter of tissue inflam-
mation [13, 16–21]. OPN likely promotes inflammation
via interaction with the CD44 receptor on macrophages
and induction of chemotaxis, and via attachment to the
b 3 integrin receptors and induction of cell spreading and
activation [16, 21, 22].
Two knockout mouse models for OPN have been de-
veloped, including the one at our institution [23, 24]. Opn
knockout mice appear anatomically normal, are fertile,
show no size differences from their wild-type littermates,
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and have histologically normal kidneys [13, 25]. However,
they do show some phenotypic differences from wild-
type mice, including resistance to ovariectomy-induced
bone resorption [26] and parathyroid hormone (PTH)-
induced enhancement of cortical bone formation [27].
Several models of acute renal injury, including ischemia
[28], ureteral ligation [29], and cyclosporine toxicity [30],
have been created in these mice. These models all demon-
strated more macrophage infiltration in wild-type mice
compared with Opn knockout mice, suggesting that OPN
is a promoter of inflammation in the kidney. OPN also has
renoprotective effects, as demonstrated by significantly
more blood urea nitrogen (BUN) and creatinine reten-
tion and increased structural renal damage following is-
chemia in Opn knockout mice compared with wild-type
mice [25]. Following ethylene glycol–induced hyperox-
aluria, there was significant intratubular deposition of
calcium oxalate monohydrate crystals in Opn knockout
mice, whereas wild-type mice were unaffected, further
supporting a renoprotective role for OPN [31]. In a mouse
model of mycobacterial infection, Opn knockout mice
had more severe infections and greater granuloma bur-
den, suggesting that the protective effects of OPN are not
limited to the kidney [32].
Many of the studies supporting the proinflammatory
and the stone-inhibiting properties of OPN have been car-
ried out in animal models of acute renal injury or in cul-
tured cells. These models are not appropriate for chronic
kidney diseases, such as hereditary stone disease, where
the disease process may have been active since birth. Over
30 hereditary stone diseases have been recognized [33],
including kidney stones associated with hypercalciuria,
hypophosphatemia, hyperoxaluria, cystinuria, hyperuri-
cosuria, and xanthinuria [34]. Our laboratory has been
investigating another genetic disorder—adenine phos-
phoribosyltransferase (APRT) deficiency—in which kid-
ney stone disease is a major phenotype [35]. APRT cat-
alyzes the synthesis of adenosine monophosphate (AMP)
from adenine, but in APRT deficiency adenine is oxidized
by xanthine dehydrogenase (XDH)—via the interme-
diate 8-hydroxyadeine (HA)—to 2,8-dihydroxyadenine
(DHA). DHA is highly insoluble at normal urine pH and
this can lead to crystal aggregation and stone formation in
many APRT-deficient patients [36]. We previously gener-
ated Aprt knockout mice [37, 38], and we have used these
mice to identify some of the early cellular and molecular
events involved in kidney stone formation [39–42]. These
mice show DHA crystals in the collecting ducts as early
as 2 days of age, and older mice have crystal deposition
throughout the renal system as well as high levels of in-
flammation and tissue fibrosis [43]. We also observed in-
creased OPN mRNA expression in kidney sections from
these mice [Tzortzaki et al, unpublished data], suggesting
that OPN may be one of the initial protective responses
of the kidney to the presence of crystals.
In this study, we examined the role of OPN in DHA
kidney stone formation by creating Aprt/Opn double
knockout mice. We hypothesized that if one of the ma-
jor roles of OPN is the inhibition of crystal aggregation
and stone formation in the urinary tract, then the onset
of stone disease would be earlier or the phenotype more
severe in double knockout mice compared with Aprt−/−
mice. The increased crystal burden in the double knock-
out mice would also be expected to lead to increased
inflammation in these mice. We studied both male and
female mice, given the gender differences in the preva-
lence of kidney stones [44–46]. Mice of all four geno-
types (Aprt−/− Opn−/−, Aprt−/− Opn+/+, Aprt+/+
Opn−/−, and Aprt+/+ Opn+/+) were examined at 6 and
12 weeks of age using biochemical, histologic, immuno-
histochemical, and in situ hybridization techniques. These
age groups were selected because at 6 weeks inflamma-
tion is first seen to develop in Aprt-deficient male mice,
and at 12 weeks inflammation and fibrosis are severe in
male mice and also evident in female mice [37, 43].
METHODS
Mouse breeding, DNA extraction, and genotyping
Animal studies were approved by the Rutgers Uni-
versity Institutional Animal Care and Use Committee.
Strain 129 mice of genotypes Aprt−/− Opn+/+ [37] and
Aprt+/+ Opn−/− [24] were mated to generate Aprt+/−
Opn+/− mice, which were then interbred to create
Aprt−/− Opn−/− mice. DNA was extracted from mice
tails at weaning and the genotypes at the Aprt and Opn
loci determined using allele-specific polymerase chain re-
action (PCR) [24, 47]. To examine the effects of Opn
background on mouse survival, pups born to Aprt het-
erozygous parents that were homozygous +/+ or −/−
for Opn were genotyped, and the observed and expected
genotype frequencies compared using chi square.
Weight and growth analysis
Male and female mice of all four genotypes were
weighed on a weekly basis from weaning to 12 weeks
of age. Each genotype included at least six mice of each
gender. Data were analyzed for rate of weight change,
range of change (maximum minus minimum weight), and
maximum achieved weight using growth curves fitted to
Gompert’s growth formula:
Weight = Asymptote−b2b3∧age
where b2 and b3 are the rate and range of weight change,
respectively, and the asymptote is the maximum weight.
Urine collection and analysis
Urine samples were collected in individual metabolic
cages (Braintree Scientific, Braintree, MA, USA); mice
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had free access to water and food during the collection
process. Approximately 400 lL urine was collected from
each mouse over a 4- to 16-hour period. Urine was stored
at −20◦C until shipped overnight on dry ice to Guy’s
Hospital, London, for analysis by reverse-phase high-
performance liquid chromatography (HPLC) [48]. The
analytes quantified included creatinine, uric acid (UA),
hypoxanthine (H), xanthine (X), adenine (A), HA, and
DHA. The data were expressed as total adenines (A, HA,
and DHA) as a fraction of total purines (UA, H, X, A,
HA, DHA) and DHA as a fraction of total adenines, and
all values were normalized to creatinine. Data for the
Aprt and Aprt/Opn knockout mice were compared using
the unpaired t test.
Tissue harvesting, crystal quantification, and histologic
evaluation
Mice were anesthetized, the left kidney removed and
frozen for crystal quantification, and the right kidney per-
fused and embedded in paraffin for histologic studies, as
previously described [43]. Briefly, crystal quantification
was carried out by examining kidney sections under po-
larized light with a Leica DMA microscope (Leica Mi-
crosystems, Bannockburn, IL, USA) and scanning with a
Polaroid DMA digital camera (Polaroid Corp., Waltham,
MA, USA). The birefringent DHA crystals were identi-
fied, and the total particle area calculated. The average
crystal area was determined from six sections from each
mouse. Renal pathology was graded on a scale of 0 to
5 for each of ten pathologic parameters, with 0 denot-
ing not affected and 5 as severely affected, as reported
elsewhere by our group [43]. The parameters included
tubular atrophy, tubular dilation, tubular debris, tubu-
lar necrosis, tubular hyperplasia, micropolyps, interstitial
nephritis, macrophage infiltration, glomerular sclerosis,
and vascular sclerosis. Scores were recorded by two in-
vestigators blinded to the identity of the mice, and the
scores were then averaged.
Immunohistochemistry and macrophage quantification
Immunohistochemistry was performed with rat an-
timouse antibody to the macrophage epitope F4/80
(Caltag Laboratories, Burlingame, CA, USA) using
reagents from Vector Laboratories (Burlingame, CA,
USA). Slides were dewaxed, rehydrated, and endoge-
nous peroxidases blocked with 0.3% hydrogen peroxide.
Tissue sections were blocked in 1:20 dilution of rabbit
serum, and 70 lL of F4/80 antibody at a dilution of 1:250
was then applied to each section overnight at 4◦C. Sec-
tions with no primary antibody were used as negative
controls. Secondary biotinylated rabbit antirat antibody
at a concentration of 5 lg/mL was applied for 1 hour,
followed by freshly prepared ABC reagent for 1 hour.
3,3′-diaminobenzidine (DAB) reagent (Sigma Fast 3,3′-
Diaminobenzidine Tablet Set) (Sigma Chemical Co., St.
Louis, MO, USA) was then applied for 2 minutes to each
section, and, after a water wash, the sections were stained
with hematoxylin, Gills formulation #2 (Fisher Scientific,
Fair Lawn, NJ, USA). Slides were dehydrated, cleared
in xylene, mounted with Cytoseal (Stephens Scientific,
Kalamazoo, MI, USA) and covered with FisherFinest
glass coverslips (Fisher Scientific).
Slides were examined using a Nikon Eclipse E800
microscope (Nikon, Melville, NY, USA), and each sec-
tion was given a score on a scale of 0 to 3. Scores
were based on the following criteria: 0, no macrophages
seen; 1, small single patch of macrophages occupying
less than 10% of the section; 2, >10% but <30% of
the section showing macrophage infiltration; and 3, more
than 30% macrophage infiltration. Two investigators who
were blinded to the origin of the sections did the scoring
independently, and the scores were averaged.
Picrosirius red staining and collagen quantification
Slides were dewaxed and rehydrated, stained for
1 hour in Direct Red 80 (0.05 g in 50 mL of saturated pi-
cric acid (Aldrich Chemical Co., Milwaukee, WI, USA),
and then rinsed twice in 0.5% acetic acid. Slides were
then dehydrated, cleared in xylene, and mounted. Slides
were examined as above and five to eight images per sec-
tion captured (at 10× magnification) using MagnaFire
software (Optronics, Goleta, CA, USA) [39, 40]. This
number of images was sufficient to capture the entire cor-
tical region of each section. Area was measured using the
Scion Image for Windows software (Scion, Fredrick, MD,
USA), available free at http://www.scioncorp.com and at
http://rsb.info.nih.gov/nih-image/ . Collagen staining was
quantified as a percentage of the entire kidney section.
XDH mRNA in situ hybridization
The sequences of the antisense and sense (used as a
negative control) XDH oligonucleotide probes were CT
GCATCCTGTCCAGGAGAGAATTGCCAAA, and
TTTGGCAATTCTCTCCTGGACAGGATGCAG, re-
spectively. The probes were labeled with fluorescein
isothiocyanate (FITC) using a 5′ end labeling kit as
described (Vector Laboratories). Slides were dewaxed,
rehydrated, and washed in diethyl pyrocarbonate
(DEPC)-treated phosphate-buffered saline (PBS) con-
taining 100 mmol/L glycine. They were then placed in
DEPC-treated PBS containing 0.3% Triton X-100, and
each section treated with 50 lL of 5 lg/mL proteinase
K for 15 minutes at 37◦C. Slides were then incubated
for 2 hours in 50 lL of prehybridization solution per
section, followed by 15 ng/lL of sense or antisense probe
overnight at 37◦C. Slides were washed sequentially in
2×, 1×, and 0.25× standard sodium citrate (SSC) at
37◦C, followed by incubation for 10 minutes with rabbit
serum diluted 1:5 in Tris-buffered saline (TBS), 3%
bovine serum albumin (BSA), and 0.1% Triton X-100.
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Table 1. Expected and observed genotype ratios for female and male
pups
Opn+/+ Opn−/−
background background
N = 74 N = 132
Aprt genotype Expected Females Males Females Males
Aprt−/− 1 2 1 1 1
Aprt+/− 2 2.9 2.6 4.4 2.84
Aprt+/+ 1 1 1.7 1.9 1.4
Chi square 2.9 1.29 28.6a 1.35
aStatistically significant. Chi-square for 2 degrees of freedom for a P value of
0.05 is 5.99.
Slides were then incubated with rabbit F(ab′) anti-FITC
conjugated to alkaline phosphatase (NovoCastra Labo-
ratories, Newcastle, UK) diluted 1:200 in TBS, 3% BSA,
and 0.1% Triton X-100. After washing with TBS, slides
were placed in alkaline phosphatase buffer for 5 minutes,
and then incubated overnight in the dark at room
temperature in this buffer containing 1% levamisole,
8% 5-bromo-5-chloro 3-indolyl phosphate, and 8% nitro
blue tetrazolium. Slides were counterstained with eosin
Y for 15 seconds, and immediately placed in 50% ethanol
for 2 minutes. Slides were then dehydrated, cleared,
mounted, and coverslipped as above.
RESULTS
Mouse survival
Mouse gender and genotypes were determined at 4
to 6 weeks of age. Any mice that died before this age
were not included in the mouse survival survey; how-
ever, dead pups that we were able to genotype did not
belong to any specific genotype group (unpublished ob-
servations). All pups were born to Aprt+/− parents ei-
ther on an Opn+/+ or Opn−/− background (Table 1).
The only group that differed significantly from Mendelian
inheritance was female offspring born on an Opn−/−
background (chi square 28.6, P < 0.001), suggesting that
Aprt−/− Opn−/− female mice have lower survival than
their Aprt−/− Opn+/+ counterparts.
Weight and growth
In male mice, the asymptote differed significantly
for the Aprt−/− Opn+/+ and wild-type mice and for
the Aprt−/− Opn−/− and wild-type mice, with wild-
type mice having greater maximum weight in each case
(P values 0.05 and <0.001, respectively). The asymp-
tote also differed significantly for Aprt−/− Opn−/− and
Aprt−/− Opn+/+ mice, with the latter having a greater
maximum weight (P value 0.045). Females showed a dif-
ferent pattern of weight change compared with males:
there was no difference for females in the maximum
weight achieved among any of the genotypes, but pa-
rameters b2 and b3 varied among genotypes. Compar-
ing the Aprt−/− Opn−/− and Aprt−/− Opn+/+ geno-
types, for example, the former group had a smaller b2
(P value 0.001) and a larger b3 (P value <0.001), indi-
cating that this group had a smaller range of weight gain.
Since the asymptotes were not different, this suggested
that at a young age the Aprt−/− Opn+/+ female mice
were smaller, but gained weight faster and reached the
same maximum weight as the Aprt−/− Opn−/− female
mice.
Urine analysis
Males tended to produce more urine than females, and
the urine output decreased in the order Aprt−/− Opn−/−
> Aprt−/− Opn+/+ > Aprt+/+ Opn+/+, and Aprt+/+
Opn−/−. The ratio of total adenines/total purines and
DHA/total adenines is a reflection of DHA formation
and stone disease severity in the knockout mice, with
higher ratios indicating more severe disease. We found
no significant difference in these ratios between gender-
matched groups of Aprt−/− Opn−/− and Aprt−/− Opn
+/+ mice at 6 weeks of age. There was a statistically sig-
nificant difference in purine excretion between males of
genotypes Aprt−/− Opn−/− and Aprt−/− Opn+/+ at 12
weeks, with a P value of 0.039 for adenines/total purines
and a P value of<0.001 for DHA/total adenines (Table 2).
However, there was no significant difference in these ra-
tios between female mice of genotypes Aprt−/− Opn−/−
and Aprt−/− Opn +/+ at 12 weeks, although both sets of
female animals excreted adenine and DHA at levels that
were comparable to those in male mice of the same geno-
types (Table 2). Mice of genotypes Aprt+/+ Opn+/+ and
Aprt+/+ Opn−/− excreted trace amounts of adenine but
no detectable amounts of DHA.
Pathology scores
Four to six mice of each gender, age, and genotype
were examined for renal pathologic changes (Table 3).
We found no significant difference in pathology scores
between gender-matched male or female mice at age
6 weeks for genotypes Aprt−/− Opn−/− and Aprt−/−
Opn+/+. The scores for 12-week-old male mice of geno-
types Aprt−/− Opn−/− were higher (2.0 ± 0.79) com-
pared with Aprt−/− Opn+/+ mice (0.9 ± 1.0), but the
difference did not reach statistical significance in the
small number of mice tested. There was a statistically
significant difference in scores between 12-week-old fe-
males for genotypes Aprt−/− Opn−/− and Aprt−/− Opn
+/+ (1.72 ± 1.20 versus 0.13 ± 0.25, P value 0.033). The
Aprt+/+ Opn+/+ and Aprt+/+ Opn−/− mice showed
no renal pathologic changes. We also noted that, in gen-
eral, Aprt−/− females had lower pathology scores than
males in matched genotype groups, regardless of Opn
genotype, but the data were not statistically significant.
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Table 2. Urinary purine content in mice by age, gender, and genotype
Genotype Number Gender Age weeks Adenines/purines DHA/adenines
Aprt+/+ Opn+/+ 3 Male 6 0.011 ± 0.010 −
Aprt+/+ Opn−/− 4 Male 6 0.009 ± 0.004 −
Aprt−/− Opn+/+ 5 Male 6 0.67 ± 0.12 0.67 ± 0.11
Aprt−/− Opn−/− 6 Male 6 0.61 ± 0.16 0.66 ± 0.10
Aprt+/+ Opn+/+ 5 Female 6 0.019 ± 0.012 −
Aprt+/+ Opn−/− 6 Female 6 0.018 ± 0.003 −
Aprt−/− Opn+/+ 7 Female 6 0.43 ± 0.13 0.66 ± 0.09
Aprt−/− Opn−/− 6 Female 6 0.44 ± 0.08 0.65 ± 0.12
aAprt+/+ Opn+/+ 1 Male 12 − −
Aprt+/+ Opn−/− 4 Male 12 0.029 ± 0.008 −
bAprt−/− Opn+/+ 6 Male 12 0.42 ± 0.22 0.54 ± 0.09
bAprt−/− Opn−/− 6 Male 12 0.69 ± 0.16 0.77 ± 0.06
Aprt+/+ Opn+/+ 3 Female 12 0.047 ± 0.008 −
Aprt+/+ Opn−/− 5 Female 12 0.050 ± 0.005 −
cAprt−/− Opn+/+ 6 Female 12 0.64 ± 0.18 0.83 ± 0.06
cAprt−/− Opn−/− 6 Female 12 0.68 ± 0.02 0.77 ± 0.06
−No detectable adenine and/or 2,8-dihydroxyadenine (DHA).
aUrine from only one animal was analyzed here, but previous work from our laboratory has shown that wild-type male mice at 12 weeks of age have no detectable
DHA in the urine, and adenine excretion is minimal ([37] and [71]).
bPurine excretion values were significantly higher in double knockout versus Aprt knockout male mice at 12 weeks of age. The respective P values were 0.039 for
adenines/total purines and <0.001 for DHA/total adenines.
cThere were no statistically significant differences in purine excretion between double knockout and Aprt knockout female mice at 12 weeks of age, even though
both groups excreted adenine and DHA at levels that were comparable to those seen in 12-week-old male mice of the same genotypes.
Table 3. Pathology score in mice by age, gender, and genotypea
Genotype Number Gender Age weeks Pathology score
Aprt−/− Opn+/+ 4 Male 6 0.3 ± 0.47
Aprt−/− Opn−/− 6 Male 6 0.92 ± 0.49
Aprt−/− Opn+/+ 4 Female 6 0.88 ± 0.75
Aprt−/− Opn−/− 6 Female 6 0.85 ± 0.97
Aprt−/− Opn+/+ 4 Male 12 0.9 ± 1.0
Aprt−/− Opn−/− 5 Male 12 2.0 ± 0.79
bAprt−/− Opn+/+ 5 Female 12 0.13 ± 0.25
bAprt−/− Opn−/− 4 Female 12 1.72 ± 1.20
aAll Aprt+/+ Opn+/+ and Aprt+/+ Opn−/− mice studied had pathology
scores of 0 regardless of age or gender.
bPathology scores in 12-week-old double knockout female mice were
significantly higher than those in Aprt knockout female mice (P value 0.033).
Crystal quantification
The mean area occupied by crystal particles in six 12-
week-old male mice of genotype Aprt−/− Opn−/− was
compared to previously published data from our group
for Aprt−/− Opn+/+ mice of the same age [43]. Consid-
ering the consistency of our prior results, in which we used
mice of the same strain and age group and the same study
design as in the present study, we did not find it neces-
sary to repeat crystal quantification in Aprt−/− Opn+/+
mice [43]. The mean values were 2400 ± 1304 mm2 and
834 ± 443 mm2, respectively (P value 0.0193), indicating
that double knockout mice had significantly more crystals
than Aprt knockout mice. The corresponding values in
12-week-old female mice of genotypes Aprt−/− Opn−/−
and Aprt−/− Opn+/+ were 199 ± 146 mm2 and 159 ±
170 mm2 (P value 0.37) respectively, indicating that, as
with urine purine excretion, there was no significant dif-
ference in crystal burden between these two genotypes.
For a given genotype, males had significantly more crys-
tals than females, with P values of <0.0001 for double
knockout males versus females and 0.0437 for Aprt−/−
Opn+/+ males versus females. The Opn−/− background
did not appear to affect the location of the crystals, as they
were found in both groups throughout the tubules and in-
terstitium, particularly in the cortex. As in our previous
study [43], there was variation in the crystal burden in age-
, gender-, and genotype-matched animals, as reflected in
the observed standard deviations.
F4/80 immunohistochemistry
We scored macrophage levels in male and female mice
of both age groups and all four genotypes (three to
six animals per group) (Fig. 1). There was no signifi-
cant difference in macrophage levels between Aprt+/+
Opn+/+ and Aprt+/+ Opn−/− mice of any age or gen-
der, or between gender-matched groups at age 6 weeks
for genotypes Aprt−/− Opn−/− and Aprt−/− Opn+/+.
The difference in macrophage levels at age 12 weeks for
genotype Aprt−/− Opn−/− versus Aprt−/− Opn+/+ ap-
proached statistical significance in male mice (2.3 ± 0.63
versus 1.4 ± 0.90) (P value 0.059) and was highly sig-
nificant in female mice (2.25 ± 0.45 versus 0.92 ± 0.29)
(P value <0.0001).
Collagen quantification
We found no significant difference in collagen levels be-
tween gender-matched groups of Aprt+/+ Opn+/+ and
Aprt+/+ Opn−/− mice at any age group, or between
Aprt−/− Opn−/− and Aprt−/− Opn+/+ mice at age
6 weeks. There was a statistically significant difference
in collagen deposition between gender-matched groups
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Fig. 1. Staining for macrophages using F4/80 antibody. (A) Twelve-week-old Aprt−/− Opn+/+ female with a macrophage score of 0.5. (B) Twelve-
week-old Aprt−/− Opn−/− female with a macrophage score of 3.0.
Fig. 2. Staining for collagen using picrosirius red. Collagen stains dark pink; the rest of the tissue is light pink or off-white. (A) A mildly affected
12-week-old Aprt−/− Opn+/+ female with a collagen content of approximately 7% of the whole section. (B) A severely affected 12-week-old
Aprt−/− Opn−/− female with a collagen content of approximately 28% of the whole section.
of both male and female mice of genotypes Aprt−/−
Opn−/− versus Aprt−/− Opn+/+ at 12 weeks of age.
The values for males were 25.5 ± 11.2 versus 8.9 ± 7.9 (P
value 0.014), and the corresponding values for females
were 10.5 ± 7.4 versus 2.3 ± 1.4 (P value 0.025). This
indicated that both male and female Aprt−/− Opn−/−
mice at age 12 weeks had more severe tissue fibrosis than
their Aprt−/− Opn+/+ counterparts (Fig. 2). These data
also indicated that Aprt−/− male mice had more severe
kidney fibrosis than genotype-matched females, regard-
less of Opn genotype.
XDH mRNA in situ hybridization
Macrophages contain XDH [49] and this could ac-
count, at least in part, for any observed differences in
inflammation and DHA crystal deposition among geno-
types. We therefore examined XDH mRNA by in situ
hybridization in kidney sections from male mice of geno-
types Aprt−/− Opn−/− and Aprt−/− Opn+/+ (five mice
per group) at age 12 weeks and with varying degrees of
macrophage infiltration. We selected these groups be-
cause they showed the greatest difference in macrophage
infiltration, in urinary purine excretion, and in crystal
aggregation. XDH was localized primarily in areas that
were densely infiltrated by macrophages (Fig. 3) and 12-
week-old Aprt−/− Opn−/− male mice showed increased
XDH mRNA expression than their Aprt−/− Opn+/+
counterparts.
DISCUSSION
We observed several important differences when com-
paring Aprt knockout mice generated on an Opn−/−
versus an Opn+/+ background. Over a 12-week period,
Aprt−/− Opn−/− male mice had a lower maximum body
weight than their Aprt−/− Opn+/+ counterparts, and fe-
male pups also had lower survival on an Opn−/− back-
ground. These observations combined suggest that the
Opn−/− background in Aprt−/− mice have a negative ef-
fect on health and survival in both males and females. The
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Fig. 3. Xanthine dehydrogenase expression by mRNA in situ hybridization in kidney sections from three 12-week-old double knockout male
mice (A, C, and D) and a 12-week-old Aprt−/− male mouse (B). The signal was detected using nitro blue tetrazolium (purple). The slides were
counterstained with eosin (pink), except for (B), which has no counterstain.
earliest weight data we recorded was at 4 to 6 weeks, but
a recent study has shown that Opn−/− embryos were sig-
nificantly smaller than wild-type embryos at gestational
ages 10.5, 15.5, and 19.5 days [50]. The Aprt−/− Opn−/−
embryos would be expected to be even smaller.
There was a significant difference in purine excre-
tion, DHA crystal deposition, and renal histopathol-
ogy between Aprt−/− Opn−/− and Aprt−/− Opn+/+
male mice at 12 weeks. The double knockout male mice
showed higher ratios of total adenines/total purines and
DHA/total adenines in the urine. These higher ratios and
the increased crystal burden in kidney sections are in-
dicative of more severe stone disease in double knock-
out versus Aprt−/− Opn+/+ male mice. In contrast
to males, there was no significant difference in urinary
purine excretion or crystal deposition between 12-week-
old Aprt−/− Opn−/− and Aprt−/− Opn+/+ female
mice, despite the fact that both these genotypes excreted
substantial amounts of adenine and DHA. This may be
due to the fact that there was a relatively small amount of
crystal material in kidneys from females compared with
males [43]. Increased macrophage infiltration and colla-
gen content in kidneys from Aprt−/− Opn−/− versus
Aprt−/− Opn+/+ female mice, despite a lack of signif-
icant difference in crystal content or purine excretion
between the two groups, again suggest that OPN is a
modifier of the inflammatory response. Estrogens are re-
ported to enhance OPN expression [51], and this may ac-
count for the reduced inflammation in Aprt−/− Opn+/+
females. Our findings also suggest that, even at compara-
ble levels of urinary DHA, there are inherent differences
in the amount of crystal deposition between male and
female kidneys.
Differences in the progression of renal disease between
male and female mice may reflect intrinsic differences in
kidney structure and function, blood pressure, or hor-
monal changes, as has been suggested for humans with
various forms of kidney disease [52–54]. Our previous
observations of increased expression of genes related to
fibrosis, tissue calcification, and transmembrane proteins
in kidneys from Aprt-deficient male mice provide support
for the gender bias in disease severity [41]. Also, it has
been suggested in a model of renal ischemia that inducible
nitric oxide synthetase (iNOS) is a crucial factor mediat-
ing the differences between male and female response
to kidney injury, with testosterone inhibiting iNOS and
thereby rendering the male kidney more susceptible
to disease [55]. Whether this is applicable to DHA
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crystal–induced injury is under investigation in our lab-
oratory. The male kidney may be less well equipped to
handle supersaturated concentrations of DHA, thus in-
creasing DHA crystal deposition with consequent fibro-
sis.
At 12 weeks of age, markers of inflammation and tis-
sue damage such as macrophage infiltration and colla-
gen deposition were generally present at higher levels
in Aprt−/− Opn−/− compared with Aprt−/− Opn+/+
mice. The fact that there was little or no difference be-
tween the genotypes at 6 weeks may at first seem puz-
zling, since many previous studies have shown OPN to
be a promoter, rather than an inhibitor, of macrophage
chemotaxis and activation but, as indicated earlier, these
studies were carried out in animal models for acute re-
nal injury [22, 28–30]. Our findings in a chronic kidney
disease model over a 12-week period support a role for
OPN as an inhibitor of crystal deposition, and they sug-
gest that, at least in males, OPN may inhibit inflammation
via a reduction in the stone burden. The relationship be-
tween OPN expression and crystal deposition in female
mice is less well defined. We are addressing these issues
using cDNA microarrays, and have to date identified a
number of novel genes as well as differences in gene ex-
pression between male and female kidneys [Vernon et al,
in preparation].
In addition to OPN deficiency, increased expression of
XDH may also account for increased DHA crystal depo-
sition and subsequent inflammation in Aprt−/− Opn−/−
versus Aprt−/− Opn+/+ male mice. In fact, both effects
may be operating in the same tissue, possibly creating a
positive feedback loop with increased crystal deposition
causing increased inflammation, which then causes in-
creased infiltration by XDH-containing macrophages. In
this case, the additional XDH would further convert ade-
nine present in the tubular fluid to DHA, thus contribut-
ing to increased DHA levels in older mice and hence
more kidney inflammation. However, Aprt−/− Opn−/−
female mice also had increased macrophage infiltration
but did not show an increase in DHA crystal deposi-
tion. Thus, the relationship between inflammation and
increased XDH expression requires verification.
OPN, which is highly negatively charged [18], likely
functions as an inhibitor of calcium oxalate monohy-
drate crystal formation via ionic interactions with the
positively charged crystal substance, thereby interrupt-
ing crystal growth and accumulation. This is supported
by work showing that alteration of the phosphorylation
level of OPN significantly alters its ability to inhibit cal-
cium oxalate monohydrate stone formation [56]. Other
work has shown that artificially created proteins that are
highly negatively charged also prevent calcium oxalate
monohydrate stone formation [57]. Similar studies with
DHA or other stone-forming crystals have not been car-
ried out, but the basic nature of the 6-amino group of
DHA provides one possible site for interaction with neg-
ative charges on OPN. Human urine has an enhanced
capacity for solubilizing DHA [58], and supersaturation
of urine with DHA has been demonstrated in some
APRT-deficient patients [35]. It remains to be determined
whether OPN or other macromolecules are involved in
these processes. DHA stones contain trace amounts of
other materials, including calcium oxalate, calcium phos-
phate, and UA [59, 60], and these may also modify the
DHA-OPN interaction. UA lacks amino groups, and it is
noteworthy that OPN had no effect on the binding of UA
crystals to renal epithelial cells [61].
Inflammation is not a major characteristic of idiopathic
calcium oxalate monohydrate stone disease [62]; thus, the
inflammation-related effects of OPN would not be ex-
pected in this disease. However, our findings regarding
OPN deficiency are applicable to metabolic disorders of
stone disease such as cystinuria [63], primary hyperox-
aluria [64], and UA urolithiasis [65] in which inflamma-
tion is a prominent feature. As with APRT deficiency, lack
of OPN and other inhibitors of stone formation would be
expected to have a negative effect on renal pathology in
these diseases.
In addition to APRT deficiency, knockout mouse mod-
els have been developed for other metabolic kidney stone
diseases, including calcium stones in Dent’s disease [66]
and type IIa Na/Pi cotransporter gene deficiency [67],
cystine stones in cystinuria [68, 69], and urate stones in
urate oxidase deficiency [70]. In each of these models,
the stone-forming agent is different but the nature and
extent of cellular injury appears to be similar in all cases.
Indicators of cellular injury include crystal growth and at-
tachment to renal tubular epithelial cells, basement mem-
brane changes and, with advancing disease, inflammation,
tissue fibrosis, and loss of renal function [43]. These ob-
servations suggest that the pathways involved in the initi-
ation and progression of renal injury may be common to
the various metabolic stone diseases. Thus, investigations
in Aprt and Aprt/Opn knockout mice have implications
for understanding other stone disease pathologies and
for evaluating the effects of potential inhibitors of stone
formation on these pathologies.
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